GCC REACH Cohort 5
David Corry, MD, Baylor College of Medicine
Project Summary: Small molecules that inhibit STAT5/6 to block core pathways driving allergic diseases and cancers
We are currently completing in vitro, in vivo, and pharmacokinetic studies for 5 closely related candidate molecules targting the STAT5 and STAT6 signaling pathways, findings from which will be used to select a lead compound to move forward with regarding more detailed PK, PD, and preclinical studies in preparation for human phase I studies. Our initial clinical indication will be atopic dermatitis (eczema), but we ultimately seek applicability to asthma, chronic sinusitis, and related airway allergic disorders.
Zhenpeng Qin, University of Texas, Dallas
Project Summary: Point-of-care diagnostic device that rapidly detects TBI by measuring biomarkers from a small blood sample
Uttam Tambar, University of Texas Southwestern Medical Center at Dallas
Project Summary: Small molecule targeted protein degrader (PROTAC) targeting prostate cancer
Sina Khorsandi & Manwal Harb, UT Southwestern
Project Summary: An ultrasound-triggered microbubble platform that safely and precisely opens the blood-brain barrier to deliver targeted therapies like antisense oligonucleotides for treating neurological diseases such as Huntington’s Disease